China’s National Medical Products Administration (NMPA) has approved Santhera Pharmaceuticals’ AGAMREE (vamorolone), used to treat Duchenne muscular dystrophy (DMD) in patients aged four years ...

Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy ...

(CNW Group/Kye Pharmaceuticals Inc.) "Muscular Dystrophy Canada (MDC) is pleased that Health Canada has granted Priority Review for AGAMREE ® (vamorolone). While corticosteroids have been a key ...

Kye Pharmaceuticals announced it has submitted a New Drug Submission, or NDS, to Health Canada for the regulatory review and approval of AGAMREE, or vamorolone. If approved, AGAMREE would be the ...

Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2024. Management will be hosting a briefing for ...

Manufacturing and supply chain To support global expansion and ensure reliable, cost-effective product availability, Santhera advanced several ...